Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Advanced Solid Tumors
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Have a life expectancy of = 12 weeks. 2) Have measurable disease or non-measurable disease per RECIST 1.1. 3) Provide a baseline archival tumor sample (Phase 1) or fresh tumor biopsy at Baseline (Phase 2).
  

You may not be eligible for this study if the following are true:

• 1) Previous solid organ or hematopoietic cell transplant. 2) Known symptomatic untreated brain metastases. 3) Prior anticancer treatment • Prior systemic anticancer treatment with chemotherapy, targeted therapy, small molecule, antibody, or investigational anticancer therapy (includes prior PD-1 or PD-L1 therapy), or other anticancer therapeutic within 4 weeks (or 5 half-lives), whichever is shorter, before the first dose of study drug (6 weeks washout for nitrosoureas or mitomycin C). 4) Previous treatment with an EZH2 inhibitor (all patients).